Edwards Lifesciences raises 2026 outlook after Q3 exceeds growth expectations

Edwards Lifesciences reported Q3 revenue growth of 11.2% year-over-year, driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapy (TMTT) segments, which grew 8% and 44% respectively. The company subsequently raised its 2026 financial outlook based on the results.